FDA approval of this prescription eye drop makes it the first and only prostaglandin with a first-line indication for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. Initially, latanoprost was only approved for second-line use.
Enfuvirtide is the first drug to be approved in a new class of anti-HIV drugs known as fusion inhibitors (see "Focus On... Enfuvirtide"). The drug interferes with the entry of HIV-1 into immune cells by inhibiting the fusion of viral and cellular membranes. This occurs when enfuvirtide prevents conformational changes required for the fusion of viral and cellular membranes by binding to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein. Enfuvirtide, in combination with other antiretroviral agents, is intended for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
New indications: Leukotriene blocker approved for treatment of seasonal allergic rhinitis
NME: New triptan approved for acute migraine treatment
New formulation: Drug increases tear production in patients with chronic dry eye due to ocular inflammation
Chronic hepatitis C therapy for patients with compensated liver disease
NME:Abused drug approved for cataplexy in tightly controlled program
NME: Option for life-threatening fungal infections
NME: Approved for all symptomatic stages of pulmonary arterial hypertension
NME: 7th ARB approved for hypertension